Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome
RR Cui
Department of Obstetrics and Gynecology and Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA
Search for more papers by this authorJD Wright
Department of Obstetrics and Gynecology and Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA
Search for more papers by this authorCorresponding Author
JY Hou
Department of Obstetrics and Gynecology and Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA
Correspondence: JY Hou, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Herbert Irving Pavilion, 161 Fort Washington Ave, Suite # 457, New York, NY 10032, USA. Email [email protected]Search for more papers by this authorRR Cui
Department of Obstetrics and Gynecology and Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA
Search for more papers by this authorJD Wright
Department of Obstetrics and Gynecology and Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA
Search for more papers by this authorCorresponding Author
JY Hou
Department of Obstetrics and Gynecology and Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA
Correspondence: JY Hou, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Herbert Irving Pavilion, 161 Fort Washington Ave, Suite # 457, New York, NY 10032, USA. Email [email protected]Search for more papers by this authorAbstract
Uterine leiomyosarcoma (LMS) are rare but aggressive tumours with poor clinical outcomes regardless of stage. Most tumours are identified by histopathology at time of surgery, and pre-operative diagnosis remains a clinical challenge. Management of early-stage LMS relies on surgical resection. Cytotoxic chemotherapy remains the mainstay of therapy for advanced-stage, recurrent or metastatic LMS, and includes single or combination doxorubicin-, ifosfamide- or gemcitabine-based regimens. Recent interest in genetic biomarkers led to developments of targeted therapies for LMS, although more research is needed to understand the molecular complexities underlying LMS to guide the development of novel treatment strategies.
Tweetable abstract
The diagnosis and treatment of uterine LMS is challenging. Novel biomarkers offer hope for future therapies.
Supporting Information
Filename | Description |
---|---|
bjo14579-sup-0001-ICMJE1.pdfPDF document, 1.2 MB | |
bjo14579-sup-0002-ICMJE2.pdfPDF document, 1.2 MB | |
bjo14579-sup-0003-ICMJE3.pdfPDF document, 1.2 MB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010; 116: 131–9.
- 2McCluggage W. Malignant biphasic uterine tumors: carcinosarcomas or metaplastic carcinomas. J Clin Pathol 2002; 55: 321–5.
- 3Wang WL, Soslow R, Hensley M, Asad H, Zannoni GF, de Nictolis M, et al. Histopathologic prognostic factors in stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases. Am J Surg Pathol 2011; 35: 522–9.
- 4Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 2004; 93: 204–8.
- 5Gockley AA, Rauh-Hain JA, del Carmen MG. Uterine leiomyosarcoma: a review article. Int J Gynecol Cancer 2014; 24: 1538–42.
- 6Fuller ASM, Young H. Uterine Cancer. Hamilton, ON: BC Decker, 2004.
- 7Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994; 18: 535–58.
- 8Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 2008; 65: 129–42.
- 9Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology 2007; 39: 55–71.
- 10Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004; 101: 1455–62.
- 11Atkins KA, Arronte N, Darus CJ, Rice LW. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol 2008; 32: 98–102.
- 12Lee CH, Turbin DA, Sung YC, Espinosa I, Montgomery K, van de Rijn M, et al. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol 2009; 22: 1519–31.
- 13Cuppens T, Tuyaerts S, Amant F. Potential therapeutic targets in uterine sarcomas. Sarcoma 2015; 2015.
- 14Taylor B, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 2011; 11: 541–7.
- 15Lusby K, Savannah KB, Demicco EG, Zhang Y, Ghadimi MP, Young ED, et al. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol 2013; 20: 2364–72.
- 16Di Cintio A, Di Gennaro E, Budillon A. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis. Recent Pat Anticancer Drug Discov 2010; 5: 1–13.
- 17Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. J Soc Gynecol Investig 2004; 11: 187–91.
- 18Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Chu Y. MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci 2011; 7: 805–14.
- 19Knosel T, Altendorf-Hofmann A, Lindner L, Issels R, Hermeking H, Schuebbe G, et al. Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier. J Clin Pathol 2014; 67: 592–8.
- 20Gaumann AK, Drexler HC, Lang SA, Stoeltzing O, Diermeier-Daucher S, Buchdunger E, et al. The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib(R)). Int J Oncol 2014; 45: 2267–77.
- 21Lieng M, Berner E, Busund B. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women. J Minim Invasive Gynecol 2015; 22: 410–4.
- 22Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994; 83: 414–8.
- 23Hinchcliff EM, Esselen KM, Watkins JC, Oduyebo T, Rauh-Hain JA, Del Carmen MG, et al. The role of endometrial biopsy in the preoperative detection of uterine leiomyosarcoma. J Minim Invasive Gynecol 2016; 23: 567–72.
- 24Kawamura N, Ichimura T, Ito F, Shibata S, Takahashi K, Tsujimura A, et al. Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma. Cancer 2002; 94: 1713–20.
- 25Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol 2009; 10: 1188–98.
- 26Cornfeld D, Israel G, Martel M, Weinreb J, Schwartz P, McCarthy S. MRI appearance of mesenchymal tumors of the uterus. Eur J Radiol 2010; 74: 241–9.
- 27Sato K, Yuasa N, Fujita M, Fukushima Y. Clinical application of diffusion-weighted imaging for preoperative differentiation between uterine leiomyoma and leiomyosarcoma. Am J Obstet Gynecol 2014; 210: 368 e1–8.
- 28Tamai K, Koyama T, Saga T, Morisawa N, Fujimoto K, Mikami Y, et al. The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol 2008; 18: 723–30.
- 29Lin G, Yang LY, Huang YT, Ng KK, Ng SH, Ueng SH, et al. Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma/smooth muscle tumor with uncertain malignant potential and benign leiomyoma. J Magn Reson Imaging 2016; 43: 333–42.
- 30Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database. Int J Gynecol Cancer 2016; 26: 1098–104.
- 31Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008; 112: 820–30.
- 32Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003; 89: 460–9.
- 33Si M, Jia L, Song K, Zhang Q, Kong B. Role of lymphadenectomy for uterine sarcoma: a meta-analysis. Int J Gynecol Cancer 2017; 27: 109–116.
- 34Wright JD, Tergas AI, Burke WM, Cui RR, Ananth CV, Chen L, et al. Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation. JAMA 2014; 312: 1253–5.
- 35Wright JD, Tergas AI, Cui R, Burke WM, Hou JY, Ananth CV, et al. Use of electric power morcellation and prevalence of underlying cancer in women who undergo myomectomy. JAMA Oncol 2015; 1: 69–77.
- 36Brohl AS, Li L, Andikyan V, Obican SG, Cioffi A, Hao K, et al. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist 2015; 20: 433–9.
- 37Einstein MH, Barakat RR, Chi DS, Sonoda Y, Alektiar KM, Hensley ML, et al. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer 2008; 18: 1065–70.
- 38Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS ONE 2012; 7: e50058.
- 39Bogani G, Cliby WA, Aletti GD. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol 2015; 137: 167–72.
- 40 US Food and Drug Administration. Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids [http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ObstetricsandGynecologyDevices/UCM404148.pdf]. Accessed 2 October 2014.
- 41Wright JD, Cui RR, Wang A, Chen L, Tergas AI, Burke WM, et al. Economic and survival implications of use of electric power morcellation for hysterectomy for presumed benign gynecologic disease. J Natl Cancer Inst 2015; 107.
10.1093/jnci/djv251 Google Scholar
- 42Reed NS, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44: 808–18.
- 43Sampath S, Gaffney DK. Role of radiotherapy treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol 2011; 25: 761–72.
- 44Bogani G, Fuca G, Maltese G, Ditto A, Martinelli F, Signorelli M, et al. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol 2016; 143: 443–7.
- 45Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 1985; 3: 1240–5.
- 46Mancari R, Signorelli M, Gadducci A, Carinelli S, De Ponti E, Sesana S, et al. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients. Gynecol Oncol 2014; 133: 531–6.
- 47Ricci S, Giuntoli RL 2nd, Eisenhauer E, Lopez MA, Krill L, Tanner EJ 3rd, et al. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? Gynecol Oncol 2013; 131: 629–33.
- 48Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 2009; 112: 563–7.
- 49Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 2013; 119: 1555–61.
- 50Burt BM, Ocejo S, Mery CM, Dasilva M, Bueno R, Sugarbaker DJ, et al. Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg 2011; 92: 1202–7.
- 51Paik E, Yoon A, Lee Y, Kim T, Lee J, Bae D. Pulmonary metastasectomy in uterine malignancy: outcomes and prognostic factors. J Gynecol Oncol 2015; 26: 270–6.
- 52Kanjeekal S, Chambers A, Fung MF, Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol 2005; 97: 624–37.
- 53Muss HB, Bundy B, DiSaia PJ, Homesley HD, Fowler WC Jr, Creasman W, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985; 55: 1648–53.
10.1002/1097-0142(19850415)55:8<1648::AID-CNCR2820550806>3.0.CO;2-7 CASPubMedWeb of Science®Google Scholar
- 54Sutton G, Blessing J, Hanjani P, Kramer P, Gynecologic Oncology G. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 96: 749–52.
- 55Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992; 166: 556–9.
- 56Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014; 15: 415–23.
- 57Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62: 226–9.
- 58Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2008; 109: 323–8.
- 59Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109: 329–34.
- 60Seddon B. GeDDiS: a prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). J Clin Oncol 2015; 33: 1180–1185.
- 61Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 (corrected). J Clin Oncol 2007; 25: 2755–63.
- 62Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ, Hensley ML. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol 2012; 124: 48–52.
- 63Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol 2015; 16: 457–64.
- 64Amant F, Lorusso D, Mustea A, Duffaud F, Pautier P. Management strategies in advanced uterine leiomyosarcoma: focus on trabectedin. Sarcoma 2015; 2015: 704124.
- 65Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol 2011; 123: 553–6.
- 66Anderson S, Aghajanian C. Temozolomide in uterine leiomyosarcomas. Gynecol Oncol 2005; 98: 99–103.
- 67Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005; 104: 1706–12.
- 68Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, Martin J, Martinez-Trufero J, Casado A, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29: 2528–33.
- 69Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016; 34: 786–93.
- 70Hyman DM, Grisham RN, Hensley ML. Management of advanced uterine leiomyosarcoma. Curr Opin Oncol 2014; 26: 422–7.
- 71Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387: 1629–37.
- 72Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer 2016; 122: 2952–2960.
- 73van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879–86.
- 74Reichardt P. The treatment of uterine sarcomas. Ann Oncol 2012; 23(Suppl 10): x151–7.
- 75Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 2015; 33: 1180–5.
- 76Hyman DM, Sill M, Cho J, Lankes H, Piekarz R, Hensley M. A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D). 2015 ASCO Annual Meeting, 2016.
- 77Demetri GD, Chawla S, Ray-Coquard I, Le Cesne A, Staddon A, Milhem M. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013; 31: 2485–92.
- 78Ioffe YJ, Li AJ, Walsh CS, Karlan BY, Leuchter R, Forscher C, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol 2009; 115: 466–71.
- 79O'Cearbhaill R, Zhou Q, Iasonos A, Soslow RA, Leitao MM, Aghajanian C, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol 2010; 116: 424–9.
- 80George S, Feng Y, Manola J, Nucci MR, Butrynski J, Morgan J. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcoma expressing estrogen and/or progesterone receptors. Cancer 2014; 120: 738–43.
- 81Zhang P, Pollock RE. Epigenetic regulators: new therapeutic targets for soft tissue sarcoma. Cancer Cell Microenviron 2014; 1: pii:e191.